Mumbai-based HiGenoMB – HiMedia has announced that Central Drugs Standard Control Organisation (CDSCO) has granted approval for commercial production for its Influenza PCR detection kit (MBPCR263).

HiMedia has developed a Multiplex Reverse Transcriptase Real‐Time PCR kit which enables the clinicians and public health laboratories to quickly diagnose influenza infection in a single tube.

Hi‐PCR® Influenza Multiplex Probe PCR Kit is capable of simultaneous screening for multiple strains of the influenza virus in less than 90 mins. It includes primer‐probe sets specific to detect RNA from the three Influenza viruses: A, B & H1N1 pdm 09 and an internal control (IC).

HiMedia has always offered open kits and instrument platform to ensure the industry always benefits from the progressive and innovative research in their laboratory and this kit is no different as it can be used to run on different Real time PCR machines in the market.

The key factor distinguishing this CE-IVD and CDSCO approved kit from other kits is that it can detect an additional target Influenza B in the same tube as other targets.

“The grave threat posed by these emerging and re‐emerging influenza viruses requires rapid laboratory detection. RT-PCR is considered as a gold standard method for influenza surveillance and diagnosis due to its high specificity, sensitivity and rapid detection and our Hi‐PCR® Influenza Multiplex Probe PCR Kit delivers just that’’ says, Dr. Rajas V Warke – Director of HiGenoMB® and Virology, HiMedia Labs.